Moderna Inc (MRNA)
$122.50
1.36 (1.12%)
MRNA Stock Quote Delayed 30 Minutes
The Freefall in Moderna Stock Will End Eventually
The discount in MRNA stock will not last forever given Moderna's steady cash flow growth potential from its Covid-19 vaccine.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
46.92B
PE Ratio
-7.82
EPS
-15.66
Volume (Avg. Vol.)
1.81M
Day's Range
$120.44 - $124.06
52-Week Range
$62.55 - $170.47
Dividend & Yield
N/A (N/A)
MRNA Stock Predictions, Articles, and Moderna Inc News
Is Moderna the Next Gilead or the Next Regeneron?
MRNA stock is seen purely as a Covid-19 play. Until Moderna can prove it's not a one-hit wonder, shares are likely to remain depressed.
INTC Stock: 9 Things to Know About Mobileye’s Fully Autonomous Shuttles Coming in 2024
Intel (INTC) stock is on the move Monday after revealing plans for all-electric, autonomous vehicles that will hit public roads in 2024.
Is MRNA Stock a Buy Following 12% Plunge? 4 Analysts Weigh In.
Here's where the expert Wall Street analysts think Moderna and MRNA stock could be headed from here, following recent weakness.
Analysts See a Dip and Then a Rebound In Moderna’s Future
MRNA stock could be at full value here if analysts' projections for lower sales in 2023 come to pass, despite a potential rebound by Q4 2023.
Value Seekers Ought To Have Moderna on Their Radar Now
Even as MRNA stock plumbs new depths, Moderna's commitment to combat Covid-19 variant strains offers hope of a turnaround.
7 Hot Stocks to Pounce on if Their Prices Drop
Here are seven hot stocks that could provide investors with the long-term returns worth considering if their prices go down this year.
MRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?
Vaccine stocks aren't enjoying a good morning today, but there's plenty of reason to suspect that they are in for a better year in 2022.
Moderna’s Long-Term Benefit Is Cursed by Short-Term Thinking
Moderna dropped after results for its mRNA flu vaccine underwhelmed investors. That proves MRNA stock is suffering from short-term thinking.
Why You Should Buy Moderna Stock at Every Dip
Moderna’s cash growth will continue as demand for booster shots and vaccines for the omicron variant increase, giving a boost to MRNA stock.
Vaccine Stocks: Why MRNA, BNTX, NVAX, PFE Stocks Are Stumbling Today
Dr. Fauci has implied that the omicron variant may not be as severe as feared. Vaccine stocks have taken a hit as a result.
7 Stocks to Buy to Give Your Portfolio a Booster Shot
With the omicron variant of Covid-19 already touching down in the U.S., here are the stocks to buy to inoculate your portfolio.
